| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 02/23/2005 | CN1583746A Methylamino-pterin derivative with inhibiting nitric oxide synthetase function |
| 02/23/2005 | CN1583162A Injection of donkey hide gelatin and its preparation |
| 02/23/2005 | CN1583160A Biological nutrient liquid for reducing blood fat and dissolving embolism and its preparation |
| 02/23/2005 | CN1583148A Preparation of oriental waterplantain pieces |
| 02/23/2005 | CN1583146A Preparation and preparing method for asthenia diseases of breath and blood circulation systems |
| 02/23/2005 | CN1583139A Preparation of dragon's blood and phospholipin composition |
| 02/23/2005 | CN1583103A Capsules for eliminating embolism and their preparation |
| 02/23/2005 | CN1583097A Health care products for improving blood circulation and relieving fatigue of eye |
| 02/23/2005 | CN1583078A Prescription of |
| 02/23/2005 | CN1583053A Zhixuebao dispersal tablets for hemostasis and their preparation |
| 02/23/2005 | CN1583041A Tongmai drops and their preparation |
| 02/23/2005 | CN1583027A Chinese medicinal powder for arresting bleeding and regenerating tissue by wound |
| 02/23/2005 | CN1583013A Composite Chinese medicine for nourishing qi, restoring yang, replenishing vital essence and generating blood and its production |
| 02/23/2005 | CN1582976A Extraction of styptic from cephalanoplos segetum |
| 02/23/2005 | CN1582950A Medicinal composition and its preparation and use |
| 02/23/2005 | CN1582944A Chlorophillni copper and sodium drops and their preparation |
| 02/23/2005 | CN1582937A Amiloride hydrochloride drops and their preparation |
| 02/23/2005 | CN1582910A Calcium phenol sulfonate dispersive tablets and their preparation |
| 02/23/2005 | CN1190491C PRV-gene and use thereof |
| 02/23/2005 | CN1190437C Pteridine compounds for treatment of psoriasis |
| 02/23/2005 | CN1190425C Six kinds of isoquinoline alkaloid |
| 02/23/2005 | CN1190424C Quinoline-containing Alpha-ketoamide cysteine and serine protease inhibitors |
| 02/23/2005 | CN1190416C Substituted phenyl alkyl nitrogen monoxide synthase inhibitor and its prepn. and use |
| 02/23/2005 | CN1190228C 'Angong' hemostaics |
| 02/23/2005 | CN1190205C Diemailing injection and its preparing process |
| 02/23/2005 | CN1190186C Carbohydrate medical solution and sulphite stabilisator in multiple compartment container and use thereof |
| 02/22/2005 | US6858642 For use in pharmaceutical, skin-protective and cosmetic formulations |
| 02/22/2005 | US6858626 Cyclic hydroxamic acid as metalloproteinase inhibitors |
| 02/22/2005 | US6858621 Mbreast and prostate anticancer agents; viricides; alopecia |
| 02/22/2005 | US6858620 For therapy of male erectile dysfunction; female arousal disorder |
| 02/22/2005 | US6858615 Phenyl guanidine sodium channel blockers |
| 02/22/2005 | US6858614 Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for treating chronic bronchitis, emphysema, cystic fibrosis, and eye disorders |
| 02/22/2005 | US6858612 Use of tetrahydropteridine derivatives as no synthase inhibitors |
| 02/22/2005 | US6858602 Compounds for the treatment of metabolic disorders |
| 02/22/2005 | US6858597 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 02/22/2005 | US6858222 Fabrication of drug loaded biodegradable polymer fibers |
| 02/22/2005 | US6858219 Methods for sterilizing male mammals |
| 02/22/2005 | US6858207 Methods and materials relating to novel CD39-like polypeptides |
| 02/22/2005 | CA2271232C Modified protein c and methods of use thereof |
| 02/22/2005 | CA2236256C A pharmaceutical composition for the treatment of autoimmune diseases |
| 02/22/2005 | CA2083243C Process for the production of a virus-free concentrate of thrombin |
| 02/17/2005 | WO2005014561A1 Compounds having thrombopoietin receptor agonism |
| 02/17/2005 | WO2005014023A1 Pharmaceutical combination of g-csf and plgf useful for blood stem cell |
| 02/17/2005 | WO2005014021A2 Use of zkw peptide for preparing an inhibitor drug against platelet aggregation |
| 02/17/2005 | WO2005013966A1 Macrophage activation inhibitor |
| 02/17/2005 | WO2005013884A2 Methods for preventing neurological events |
| 02/17/2005 | WO2005013691A1 Use of boranocarbonates for the therapeutic delivery of carbon monoxide |
| 02/17/2005 | WO2004113278A3 Acylsulfamide inhibitors of factor viia |
| 02/17/2005 | WO2004103264A3 Hemostatic antibacterial composition and products incorporating the same |
| 02/17/2005 | WO2004089278A3 Sexual hygienic composition |
| 02/17/2005 | WO2004070050A3 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors |
| 02/17/2005 | WO2003104412A3 Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects |
| 02/17/2005 | WO2003099192A8 Bis-aromatic alkanols |
| 02/17/2005 | WO2002074913A3 Nucleic acid-associated proteins |
| 02/17/2005 | US20050038259 Elastase release inhibitors; such as 19-(1H-tetrazol-5-yl)nonadec-6-en-5-ol |
| 02/17/2005 | US20050038061 6-Aminomorphinane derivatives, method for production and use thereof |
| 02/17/2005 | US20050038060 Spiropoperidine compounds as ligands for orl-1 receptor |
| 02/17/2005 | US20050038037 N-(naphth-2-ylaminocarbonylacetyl)- or N-(naphth-2-ylcarbonylamino- acetyl)- piperazine derivatives, e.g., 2-[((4-(ethoxycarbonyl)piperazin-1-yl)carbonylmethyl)carbonyl]aminonaphthalene; useful as antithrombotic agents |
| 02/17/2005 | US20050038030 For thromboembolic disorder from unstable angina, acute coronary syndrome, myocardial infarction, ischemia, stroke, atherosclerosis |
| 02/17/2005 | US20050038027 Melanocortin-4 receptor agonists; obesity, type II diabetes; such as N-(2-(2-(2,4-dichlorophenyl)ethyl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl) -3-methyl-N'-(2,6,6-trimethylbicyclo(3.1.1)hept-3yl)piperazine-1-carboximidamide |
| 02/17/2005 | US20050038014 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 02/17/2005 | US20050038009 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- alpha -[N-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine |
| 02/17/2005 | US20050037976 Hematopoietic stimulation |
| 02/17/2005 | US20050037971 Use of hepcidin as a regulator of iron homeostasis |
| 02/17/2005 | US20050037494 Using antisense agents to reduce and/or prevention genic expression associated with cardi-vascular complications; gene therapy |
| 02/17/2005 | US20050037077 Absorption in upper part of gastrointestinal system; microcapsules coated with hydrophilic polymer such as Eudragit |
| 02/17/2005 | US20050037009 Methods and reagents for protease inhibition |
| 02/17/2005 | US20050037006 Antithrombotic agents |
| 02/17/2005 | US20050037005 5c8 Antigen |
| 02/17/2005 | US20050036983 In vivo use of water absorbent polymers |
| 02/17/2005 | CA2535446A1 Methods for preventing neurological events |
| 02/17/2005 | CA2535066A1 Macrophage activation inhibitor |
| 02/17/2005 | CA2534415A1 Therapeutic delivery of carbon monoxide |
| 02/16/2005 | EP1506967A1 Dipeptidyl peptidase inhibitors |
| 02/16/2005 | EP1506951A1 Preparation and application of transhintotalphenolic acid |
| 02/16/2005 | EP1506785A1 Composition for treating or preventing hyperuricemia |
| 02/16/2005 | EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 02/16/2005 | EP1506214A1 6-11 bicyclic ketolide derivatives |
| 02/16/2005 | EP1506192A1 Substituted pyrroline kinase inhibitors |
| 02/16/2005 | EP1506187A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 02/16/2005 | EP1506183A1 Method of forming iron hydroxypyrone compounds |
| 02/16/2005 | EP1506180A1 Thiazolidine-4-one derivative, method for preparing the same, and pharmaceutical composition containing the same |
| 02/16/2005 | EP1506176A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/16/2005 | EP1506162A2 Synthesis of benzonitriles and benzimidates |
| 02/16/2005 | EP1506040A2 Selective inos inhibitors for the treatment of respiratory diseases and conditions |
| 02/16/2005 | EP1506011A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/16/2005 | EP1506002A2 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies |
| 02/16/2005 | EP1505973A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 02/16/2005 | EP1505966A1 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
| 02/16/2005 | EP1505965A1 Use of valsartan ot its metabolite to inhibit platelet aggregation |
| 02/16/2005 | EP1425258A4 Hydroxyeicosenoic acid analogs |
| 02/16/2005 | EP1395553B1 Pyrrolidine derivatives as factor xa inhibitors |
| 02/16/2005 | EP1377584B1 Novel cyclohexenyl phenyl diazepines as vasopressin and oxytocin receptor modulators |
| 02/16/2005 | EP1296698A4 Therapeutic agents - ii |
| 02/16/2005 | EP1296697A4 Therapeutic agents - i |
| 02/16/2005 | EP1294741B1 Dipeptide inhibitors for the blood-clotting factor xa |
| 02/16/2005 | EP1268463B1 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
| 02/16/2005 | EP1253917B1 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 02/16/2005 | EP1246792A4 Compounds and compositions for delivering active agents |
| 02/16/2005 | EP1240166B1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases |